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AbstractMutations in the TANK-binding kinase 1 (TBK1) gene have recently been shown to
cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The pheno-
type is highly variable and has been associated with behavioral variant FTD, primary pro-
gressive aphasia, and pure ALS. We describe the clinical, anatomical, and pathological
features of a patient who developed corticobasal syndrome (CBS)/progressive nonfluent
aphasia (PNFA) overlap. The patient presented with progressive speech difficulties and later
developed an asymmetric akinetic–rigid syndrome. Neuroimaging showed asymmetrical
frontal atrophy, predominantly affecting the right side. There was a strong family history
of neurodegenerative disease with four out of seven siblings developing either dementia
or ALS in their 50s and 60s. The patient died at the age of 71 and the brain was donated
for postmortem analysis. Histopathological examination showed frontotemporal lobar
degeneration TDP-43 type A pathology. Genetic screening did not reveal a mutation in
the GRN,MAPT, or C9orf72 genes, but exome sequencing revealed a novel p.E703X mu-
tation in the TBK1 gene. Although segregation data were not available, this loss-of-function
mutation is highly likely to be pathogenic because it is predicted to disrupt TBK1/optineurin
interaction and impair cellular autophagy. In conclusion, we show that TBK1mutations can
be a cause of an atypical parkinsonian syndrome and screening should be considered in
CBS patients with a family history of dementia or ALS.
[Supplemental material is available for this article.]
INTRODUCTION
Mutations in the tumor necrosis factor receptor-associated factor NF-κB activator (TANK)-
binding kinase 1 (TBK1) gene, located on Chromosome 12, have recently been described
as a cause of familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis
(ALS) (Cirulli et al. 2015; Freischmidt et al. 2015; Pottier et al. 2015). Patients have usually pre-
sented with either behavioral variant FTD, pure ALS, or a combination of both (FTD–ALS),
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and multiple different syndromes have been observed within the same family (Van
Mossevelde et al. 2016).
TBK1 is a 729-amino acid protein kinase that acts as a mediator of inflammation and
autophagy (Marion 2014; Ahmad et al. 2016). It is a ubiquitously expressed serine–threonine
kinase belonging to the “noncanonical IκB kinases” (IKKs) (Marion 2014; Ahmad et al. 2016).
More than 40mutations have been found in the TBK1 gene that cause either a frameshift or a
premature stop codon, likely leading to a truncated or absent protein product (Freischmidt
et al. 2017). Similar to mutations in the progranulin (GRN) gene, these are likely to be path-
ogenic through haploinsufficiency (Freischmidt et al. 2015). More than 50 missense muta-
tions have also been described with unclear pathogenicity (Freischmidt et al. 2017).
Further functional work will be required to assess whether these are truly pathogenic or could
represent risk factors for FTD and ALS.
Corticobasal syndrome (CBS) is a rare neurodegenerative disease characterized by pro-
gressive asymmetrical rigidity and apraxia (Armstrong et al. 2013). Other features include
myoclonus, akinesia, dystonia, alien limb phenomena, and cognitive impairment. CBS is
pathologically heterogeneous with only around half of cases being associated with the
typical histological findings of corticobasal degeneration (Ling et al. 2010). Other cases
are caused by progressive supranuclear palsy, Alzheimer’s disease, and, more rarely, TDP-
43 pathology. The majority of cases of CBS are sporadic but familial cases have been rarely
described in association with mutations inGRN, microtubule-associated protein tau (MAPT),
Chromosome 9 open reading frame 72 (C9orf72), and colony-stimulating factor 1 receptor
(CSF1R) (Masellis et al. 2006; Rademakers et al. 2012; Anor et al. 2015).
In this report, we describe the clinical, radiological, and pathological features of a 59-yr-
old woman who developed CBS in association with primary progressive aphasia caused by a
novel TBK1 mutation.
RESULTS
Clinical Presentation and Family History
A right-handed woman presented at the age of 59 with a 6-mo history of progressive speech
problems. Her initial symptoms were of knowing what she wanted to say but not being able
to get the words out. There were no other cognitive, behavioral, or motor symptoms. Her
symptoms slowly progressed over the next 2 yr andwhen assessed at the age of 62, her prob-
lems continued to be of impaired speech output without any other cognitive symptoms.
Cranial nerve and limb neurological examinations were normal, but she had a reduced score
of 81/100 on the Addenbrooke’s Cognitive Examination (subscores: 18/18 attention and ori-
entation, 20/26 memory, 7/14 fluency, 24/26 language, and 12/16 visuospatial). Formal psy-
chometric testing was not performed but she was assessed on the Boston Naming Test,
where she scored within the normal range (57/60). Blood tests and CSF examination were
normal, as was electromyography. However, an MRI brain scan was abnormal, showing focal
right frontal lobe atrophy (Fig. 1; Supplemental Movie S1). A diagnosis of PNFA was made.
Neither of her parents had a neurodegenerative illness, but her father died of myocardial
infarction in his 40s. Themother died aged 83 of a stroke. Shewas one of seven siblings: One
sister developed a rapidly progressive dementia in her 60s (II.2), two other sisters were diag-
nosed with ALS in their 40s (II.3) and 60s (II.4), and another sister was thought to have ALS
and dementia with onset in her 50s (II.6), highlighting the variability of clinical presentations
within the same family (Fig. 2A). II.2 first developed symptoms aged 65, presenting with a
change in behavior. She became childlike in her demeanor and exhibited changes in appe-
tite, developing a very sweet tooth and tending to overfill her mouth. Her behavior decline
was rapid, deteriorating over a period of 6 mo. She was diagnosed with dementia and died
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aged 68. II.3 first developed symptoms aged 39 and was reported to have difficulties with
her speech and swallowing, which progressed rapidly over a period of 3 mo; she was not re-
ported to have any cognitive or behavioral difficulties. She was diagnosed with ALS and died
aged 48. II.4 developed symptoms aged 59 and was diagnosed with ALS; however, she was
not reported to have any difficulties with her speech or swallowing. Her symptoms pro-
gressed over a period of 12 mo. She died aged 69. II.6 developed symptoms aged 60.
She was thought to have ALS and memory problems, but little was known of her condition
as she reportedly became a recluse, refusing to leave the house or let anyone visit her.
She died aged 68.
The patient’s speech problems progressed and, when reassessed 4 yr into her illness, she
had minimal speech output with evidence of orofacial apraxia. She had developed impaired
swallowing and had had a PEG tube inserted. She had also developed an asymmetric aki-
netic–rigid syndrome with apraxia, dystonia, and myoclonus, affecting the left arm and, to
a lesser extent, the left leg more than the right side. She also had difficulty initiating saccadic
eye movements. Repeat electromyography of the four limbs was normal. A diagnosis of CBS
was made.
She continued to progress over the next few years with worsening comprehension of
speech and increasing difficulty with movement. By 8 yr into the illness, she became depen-
dent on nursing care for all her personal care needs and was not assessed further following
this. Although not formally assessed, the cognitive impairment at this stage was of sufficient
severity to significantly interfere with activities of daily living and contributed to her loss of
independence. She died from bronchopneumonia at the age of 71, after a progressive neu-
rodegenerative illness lasting 12 yr in duration.
The patient consented to brain donation, and after death her brain was assessed using
standard neuropathological methods at the Queen Square Brain Bank, where tissue is stored
Figure 1. Magnetic resonance imaging scans demonstrating frontal lobe atrophy, with the right side more
markedly affected. (Top) T1-weighted sagittal views. (Bottom) T2-weighted axial (left) and coronal (middle
and right) views.
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for research under a licence from the UK Human Tissue Authority. Representative areas of
neocortex, basal ganglia, hippocampus, midbrain, pons, medulla, and cerebellum were ex-
amined using routine stains, with additional immunohistochemical staining for Aβ, tau (AT8),
TDP-43, ubiquitin, p62, GFAP, CD68, and α-synuclein. Macroscopic examination showed
marked atrophy of the frontal and parietal lobes and, to a lesser extent, atrophy of the tem-
poral lobe with severe dilatation of the lateral ventricle. There was severe atrophy of the
amygdala with moderate atrophy of the hippocampus. The caudate and globus pallidus
were also atrophic and there was marked pallor of the substantia nigra and locus coeruleus
(Fig. 3). Histological examination of the left hemisphere showed marked cortical pathology
with thinning, neuronal loss, and spongiosis, most severe in the frontal and parietal lobes.
There was neuronal loss and gliosis in the caudate and globus pallidus, and this was severe
in the substantia nigra. TDP-43 immunohistochemistry demonstrated short neurites and neu-
ronal cytoplasmic inclusions corresponding to cortical pathology characteristic in the FTLD–
TDP type A subtype. Immunohistochemical staining for hyperphosphorylated tau showed
features of argyrophilic grains with neurofibrillary tangles in the hippocampus accompanied
by grains in the hippocampal CA1 subregion and the subiculum, in addition to small num-
bers of bushy astrocytes in cortical regions. There was no Aβ or α-synuclein pathology.
A
B
Figure 2. (A) Pedigree indicating the diversity of familial neurological disease present among familymembers.
(B) Structure of the TBK1 gene (NM_013254) and reserve-complement chromatogram showing the position of
the c.2107G>T variant identified in the index case (II.7), leading to a 27-amino acid deletion in the CC2domain
of the TBK1 protein. (AAD) Age at death, (AAO) age at onset, (S/T) serine-threonine, (UbLD) ubiquitin-like
domain, (CC1) coiled-coil domain 1, (CC2) coiled-coil domain 2.
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The right hemisphere was not available for immunohistochemistry, as it was snap-frozen for
molecular analysis.
Genomic Analysis
Genetic screening excluded mutations in GRN and MAPT (exons 1 and 9–13).




Figure 3. (A) A coronal slice from the left cerebral hemisphere demonstrates ventricular dilatation with atrophy
of the frontal lobe, caudate nucleus, and amygdala. In the midbrain, there is severe pallor of the substantia
nigra (arrows). (B) Histological examination of the frontal lobe by hematoxylin and eosin staining shows thin-
ning and spongiosis of the cortex. (C ) Severe loss of pigmented neurons in the substantia nigra is confirmed
with residual free neuromelanin in the neuropil (arrow and inset). (D) TDP-43 immunohistochemistry in the fron-
tal lobe shows neurons with loss of the normal nuclear staining pattern and containing cytoplasmic inclusions
(arrows and inset), in addition to scattered short neurites (arrowheads). (E,F) Argyrophilic grains in the subicu-
lum are highlighted by immunohistochemistry for p62 (E) and four-repeat tau isoforms (F ). Scale bar, 300 µm
(B), 120 µm (C ), 30 µm (C inset, D,E,F ), and 20 µm (D inset).
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ALS (DeJesus-Hernandez et al. 2011; Renton et al. 2011), were also excluded. Exome se-
quencing was undertaken to identify potential pathogenic variants. The patient was found
to harbor a novel c.2107G>T (p.E703X: NM_013254.4) variant in exon 20 of the TBK1
gene (Table 1; Supplemental Table S1). Sanger sequencing of exon 20 confirmed the pres-
ence of a heterozygous G>T substitution at nucleotide 2107 (Fig. 2B). This variant was not
seen in more than 138,000 unrelated exome and genome sequences from the gnomAD da-
tabase (0/138,632; http://gnomad.broadinstititue.org/). This nonsense variant was located in
the carboxy-terminal coiled-coil domain 2 (CC2) and results in a premature stop codon, lead-
ing to a predicted truncated protein product. Segregation of the variant could not be verified
because of the unavailability of blood samples from additional family members.
DISCUSSION
Here, we describe the presence of a novel TBK1 mutation in a patient who presented clin-
ically with a CBS–PNFA overlap syndrome, radiologically with asymmetric frontal lobe atro-
phy, and with FTLD–TDP type A pathology at postmortem examination of brain tissue.
Although we did not have access to blood samples to test segregation of the mutation
within the family, this variant is highly likely to be pathogenic, as it results in a premature
stop codon, and hence a truncated protein product. Heterozygous loss of function variants
have been shown to be enriched in familial FTD–ALS pedigrees and are likely to be patho-
genic through nonsense-mediated mRNA decay (NMD) and global reduction of protein lev-
els (Cirulli et al. 2015; Freischmidt et al. 2015; Pottier et al. 2015). However, NMD associated
with the heterozygous p.E703X mutation described here is unlikely, because of the position
of the premature stop codon in the gene (Hug et al. 2016). Instead, loss of the crucial highly
conserved CC2 protein domain is likely to result in the abrogation of the interaction and
complex formation with TBK1-associated adaptors that are essential in regulating TBK1 ac-
tivation and its subcellular localization (Gonçalves et al. 2011). Mutations within this domain
have been shown to disrupt the TBK1/OPTN (optineurin) interaction (Freischmidt et al.
2015). OPTN is an important autophagy receptor critical for the degradation and clearance
of intracellular pathogens, protein aggregates, and damaged organelles. The carboxy-ter-
minal domain of TBK1 binds to the amino-terminal region of OPTN to form the TBK1/
OPTN complex (Li et al. 2016). TBK1 is also thought to directly phosphorylate OPTN to pro-
mote autophagy.Mutations in both the carboxy-terminal domain of TBK1 and the amino-ter-
minal domain of OPTN have been implicated in ALS and other neurodegenerative diseases
(Maruyama et al. 2010; Pottier et al. 2015), and it is likely that disruption of the formation of
the TBK1/OPTN complex impairs critical autophagy processes that are vital to maintaining
cellular homeostasis (Li et al. 2016). Interestingly, TBK1 has also been shown to act on a com-
mon pathway with C9orf72 complexes to regulate autophagy in neuronal cells (Sellier et al.
2016). It was found that by promoting the phosphorylation of one of the proteins in this com-
plex (SMCR8), TBK1 is important for C9orf72-mediated autophagy, thus providing another
mechanism by which TBK1 mutations could lead to neurodegeneration. Disruption in
autophagy processes has been implicated in other neurodegenerative conditions such as
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Parkinson’s disease, in which mutations in PINK1 and Parkin are believed to function in a
common pathway to promote defective mitochondrial clearance via autophagy (Barodia
et al. 2017).
Clinically, this patient developed an overlap syndrome of primary progressive aphasia
(PNFA) followed by CBS. This is a well-described overlap of neurodegenerative syndromes,
but only one other case has been described in association with a TBK1 frameshift mutation
(Caroppo et al. 2015). Neuroanatomically, there are few reports of the imaging features of
TBK1-associated disease. Patterns of atrophy are variable and likely reflect the areas most
affected by neurodegeneration. In most cases, atrophy is asymmetric and predominantly in-
volves the temporal lobe (Caroppo et al. 2015; Koriath et al. 2016). However, atrophy that
predominantly affects the frontal cortex, mesencephalon, and cerebellum have all been de-
scribed, and it is plausible that atrophy patterns correlate with the main clinical phenotype
(Wilke et al. 2018). The neuropathological features associated with TBK1 mutations have
also been described infrequently. Most cases reported so far had TDP-43 type B pathology
(Freischmidt et al. 2015; Pottier et al. 2015; Van Mossevelde et al. 2016), but TDP-43 type A
pathology has also been described (Pottier et al. 2015; Koriath et al. 2017). Whether there is
a correlation between mutation type and/or location within the different TBK1 domains and
the pathological consequences remains to be elucidated. Of interest, this case also had tau-
positive argyrophilic grains, as previously reported, raising the possibility that this additional
pathology might be a feature of the disease (Koriath et al. 2017).
Mutations in TBK1 are the fourth most common cause of familial FTD, and the second
most common cause of a combined FTD–ALS syndrome (Dols-Icardo et al. 2018). More re-
cently, TBK1mutations have been found in patients with progressive supranuclear palsy and
progressive cerebellar ataxia syndromes, expanding the phenotypic spectrum of TBK1-
associated disease (Wilke et al. 2018). Only one other case of familial CBS–PNFA overlap
syndrome has been reported in the literature thus far, carrying a frameshift mutation (p.
Thr156ArgfsX6) affecting the kinase domain of TBK1 (Caroppo et al. 2015). The first de-
scribed cause of familial CBS was due to a mutation in the MAPT gene (Masellis et al.
2006), but this is relatively rare (van Swieten 2007) and tends to cause a syndromewith prom-
inent behavioral symptoms. A familial CBS overlap with primary progressive aphasia is more
commonly associated with GRNmutations (van Swieten and Heutink 2008), but is nonethe-
less a rare phenotype ofGRN. More recently, case reports of familial CBS caused byC9orf72
and CSF1R have been described, but this is also rare and an unusual phenotype for these
genes. It is increasingly recognized that neurodegenerative disorders are pathologically
and genetically heterogeneous. Similar clinical syndromes can have multiple underlying pa-
thologies and genetic cause, and mutations in a single gene can manifest with diverse clin-
ical phenotypes, often in the same kindred. In this context, clearly exemplified by this case
report, the exact definition of a clinicopathological entity is increasingly reliant on a genetic
diagnosis.
In summary, we describe a novel TBK1mutation in a patient who presented with a CBS–
PNFA overlap and who had a family history of dementia and ALS. The presence of a family
history in a patient with CBS should lead to testing for mutations in the known FTD genes.
However, if these are negative sequencing for mutations in TBK1 should be considered.
This case highlights the importance of genetic exome sequencing as a diagnostic tool in pa-
tients presenting with CBS and associated neurodegenerative disorders.
METHODS
Briefly, for whole-exome sequencing, the sample library was prepared using Illumina
Nextera Rapid Capture kits with paired-end sequencing performed using the Illumina
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HiSeq2000 (Illumina). The sample was sequenced to an average coverage of 39.42 reads
with a mean read length of 177.23 bp (Supplemental Table S2). All reads were subsequently
aligned using BWA (Li and Durbin 2009) against UCSC hg19 reference genome. Variant call-
ing and quality-based filtering for all samples were done using GATK (McKenna et al. 2010).
Variants were annotated with ANNOVAR (Wang et al. 2010) with allele frequency data from
the gnomAD browser, as well as with predicted impact of variants (Kircher et al. 2014).
For Sanger sequencing, exon 20 was amplified using specific primers (F 5′-CAG
CTTCCAGTGGAATCAAACA-3′ and R 5′-AGGCATCACAGATACACAATCA-3′). The ampli-
fied PCR product was enzymatically cleaned up and sequenced on both strands using a
BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems). Sequencing products
were run on a 3730 DNA Analyser (Applied Biosystems) and analyzed using Sequencher
DNA Sequence Analysis software (Gene Codes Corp.).
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